Sol-Gel Builds Awareness Of Rare Skin Condition, Generates Leads

Recruiting for ultra-rare conditions like Gorlin syndrome presents a unique set of hurdles. With an estimated prevalence of just 1 in 31,000, identifying eligible participants is a race against time. This was the situation Sol-Gel Technologies faced when patients face the relentless development of basal cell carcinoma lesions. This case study explores a strategic pivot in clinical recruitment, detailing how a rapid, multi-country HCP awareness initiative helped bridge the gap between a critical preventive therapy and the patients who need it most.

By shifting the focus toward high-touch engagement with healthcare providers across seven countries, the project achieved open and click rates that significantly outpaced industry benchmarks. The insights gathered highlight the necessity of agility in clinical operations—showing how a campaign launched in under a month can reignite momentum for a stalling trial. Readers will gain a deeper understanding of the mechanics behind successful international recruitment, the impact of re-engagement strategies for interested clinicians, and how to maintain momentum when the patient population is exceptionally small. It serves as a practical roadmap for overcoming the logistical and geographical barriers inherent in rare disease drug development.